UY32750A - Imidazoles sustituidos y uso de los mismos - Google Patents
Imidazoles sustituidos y uso de los mismosInfo
- Publication number
- UY32750A UY32750A UY0001032750A UY32750A UY32750A UY 32750 A UY32750 A UY 32750A UY 0001032750 A UY0001032750 A UY 0001032750A UY 32750 A UY32750 A UY 32750A UY 32750 A UY32750 A UY 32750A
- Authority
- UY
- Uruguay
- Prior art keywords
- imidazols
- replaced
- same
- beta
- limited
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/88—Nitrogen atoms, e.g. allantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a nuevos compuestos de fórmula (I) y sus composiciones farmacéuticas. Además, la presente invención se refiere a métodos terapéuticos para el tratamiento y/o prevención de patologías relacionadas con AB(beta) tales como síndrome de Down, angiopatía B(beta) amiloide tal como pero sin limitarse a angiopatía amiloide cerebral o hemorragia cerebral hereditaria, trastornos asociados con el deterioro cognitivo tal como pero sin limitarse a deterioro cognitivo leve (MCI, por su sigla inglés) y enfermedad de Alzheimer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22253509P | 2009-07-02 | 2009-07-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY32750A true UY32750A (es) | 2011-01-31 |
Family
ID=43411290
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001032750A UY32750A (es) | 2009-07-02 | 2010-07-01 | Imidazoles sustituidos y uso de los mismos |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR077365A1 (es) |
TW (1) | TW201103893A (es) |
UY (1) | UY32750A (es) |
WO (1) | WO2011002408A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA108363C2 (uk) | 2009-10-08 | 2015-04-27 | Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування | |
US8415483B2 (en) | 2010-12-22 | 2013-04-09 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
US20120165346A1 (en) * | 2010-12-22 | 2012-06-28 | Astrazeneca Ab | Compounds and their use as BACE inhibitors |
EP2780321B1 (en) | 2011-10-10 | 2015-12-30 | Astrazeneca AB | Mono-fluoro beta-secretase inhibitors |
US9000182B2 (en) * | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | 2H-imidazol-4-amine compounds and their use as BACE inhibitors |
US9000185B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cycloalkyl ether compounds and their use as BACE inhibitors |
US9000183B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-indene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US9000184B2 (en) | 2012-06-20 | 2015-04-07 | Astrazeneca Ab | Cyclohexane-1,2′-naphthalene-1′,2″-imidazol compounds and their use as BACE inhibitors |
US10548882B2 (en) * | 2012-06-21 | 2020-02-04 | Astrazeneca Ab | Camsylate salt |
CN114989103B (zh) * | 2022-06-09 | 2024-07-09 | 杭州科巢生物科技有限公司 | 一种2-甲氧基-3-(1-甲基-1h-1,2,4-三唑-3-基)苯胺的制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200734311A (en) * | 2005-11-21 | 2007-09-16 | Astrazeneca Ab | New compounds |
CN101360716A (zh) * | 2005-11-21 | 2009-02-04 | 阿斯利康(瑞典)有限公司 | 新颖的2-氨基-咪唑-4-酮化合物及其在制备用于治疗认知缺损、阿尔茨海默病、神经变性和痴呆的药物中的用途 |
TW200831484A (en) * | 2006-12-20 | 2008-08-01 | Astrazeneca Ab | New compounds |
WO2008076044A1 (en) * | 2006-12-20 | 2008-06-26 | Astrazeneca Ab | Novel 2-amino-5, 5-diaryl-imidazol-4-ones |
TW200902503A (en) * | 2007-05-15 | 2009-01-16 | Astrazeneca Ab | New compounds |
-
2010
- 2010-07-01 AR ARP100102352A patent/AR077365A1/es unknown
- 2010-07-01 UY UY0001032750A patent/UY32750A/es unknown
- 2010-07-01 TW TW099121731A patent/TW201103893A/zh unknown
- 2010-07-02 WO PCT/SE2010/050760 patent/WO2011002408A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
TW201103893A (en) | 2011-02-01 |
AR077365A1 (es) | 2011-08-24 |
WO2011002408A1 (en) | 2011-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY32750A (es) | Imidazoles sustituidos y uso de los mismos | |
UY32751A (es) | Imidazoles sustituidos y uso de los mismos | |
CR20130308A (es) | Compuestos y su uso como inhibidores de bace | |
CR20110255A (es) | Nuevos compuestos 578 | |
CO6290683A2 (es) | Compuestos de pirido imidazolinas heterociclicas y sus composiciones como inhibidores de c-met | |
GT200900294A (es) | Compuestos amino-heterocíclicos | |
ECSP11010754A (es) | Derivados de triazol útiles para el tratamiento de enfermedades | |
DOP2012000067A (es) | Compuestos de dióxido de iminotiadiazina como inhibidores de enzima de disociacion de app de sitio beta ( bace), composiciones, y su uso | |
UY35612A (es) | Compuestos de sulfonamida bicíclicos como inhibidores de los canales de sodio | |
CL2007001887A1 (es) | Compuestos derivados de bifensustuidas por tetrazol; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades asociadas con los receptores purinergicos de p2x, tales como trastornos gastrointes | |
MX2013004307A (es) | Derivados de arilamida como bloqueadores de ttx-s. | |
ECSP13013048A (es) | Spiro-[1,3]-oxacinas y spiro-[1,4]-oxacepinas como inhibidores | |
CL2008003591A1 (es) | Compuestos derivados de isoxazolo-piridina sustituida; procedimiento de preparacion; composicion farmaceutica; y su uso en el tratamiento de trastornos cognitivos y alzheimer, mediado por la union al sitio de fijacion del receptor gaba a alfa 5. | |
ECSP11011517A (es) | Compuestos antivirales | |
CR20130588A (es) | Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2 | |
CR20140071A (es) | Nuevos compuestos de 4-piperidinilo para uso como inhibidores de la tankirasa | |
UY32622A (es) | Nuevos compuestos para el tratamiento de patologías relacionadas con ab(beta) | |
ECSP14027564A (es) | Agentes para tratar trastornos que implican la modulación de receptores de rianodina | |
CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
CL2012001461A1 (es) | Compuestos derivados de difenil-pirazolopiridinas, moduladores del receptor nuclear nurr-1; compuestos intermediarios; composición farmacéutica; y su uso para el tratamiento y prevención de enfermedades neurodegenerativas, traumatismos cerebrales, enfermedades inflamatorias, osteoporosis, cáncer, entre otras. | |
ECSP088807A (es) | Tetrahidro-pirimidoazepinas como moduladores del potencial transitorio de receptor vaillinoide 1 (trpv1) | |
IN2014MN02056A (es) | ||
DOP2011000134A (es) | Lactamas como inhibidores de beta secretasa | |
IN2014MN01982A (es) | ||
CL2011000865A1 (es) | Compuestos derivados de isoquinolinona; composicion farmaceutica que los comprende; y uso del compuesto para tratar enfermedades tales como psicosis, esquizofrenia, alzheimer entre otras. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DESI | Application deemed to be withdrawn |
Effective date: 20130125 |